Susquehanna reaffirmed their neutral rating on shares of Humana Inc. (NYSE:HUM) in a research report report published on Thursday. The brokerage currently has a $180.00 price objective on the insurance provider’s stock.
HUM has been the subject of a number of other research reports. Argus restated a hold rating on shares of Humana in a report on Tuesday, August 23rd. JPMorgan Chase & Co. cut Humana from an overweight rating to a neutral rating and reduced their price objective for the stock from $196.00 to $150.00 in a report on Friday, July 8th. RBC Capital Markets restated a buy rating and set a $224.00 price objective (up previously from $220.00) on shares of Humana in a report on Friday, July 22nd. Jefferies Group upgraded Humana from a hold rating to a buy rating and boosted their price objective for the stock from $158.89 to $210.00 in a report on Monday, July 18th. Finally, Wolfe Research assumed coverage on Humana in a report on Tuesday, June 28th. They set a market perform rating and a $244.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $200.50.
Humana (NYSE:HUM) opened at 173.27 on Thursday. The stock has a 50 day moving average price of $175.62 and a 200-day moving average price of $175.43. The firm has a market capitalization of $25.83 billion, a PE ratio of 26.62 and a beta of 0.90. Humana has a one year low of $150.00 and a one year high of $191.65.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 3rd. The insurance provider reported $2.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.23 by $0.07. Humana had a return on equity of 11.11% and a net margin of 1.76%. The company earned $14 billion during the quarter, compared to analysts’ expectations of $13.59 billion. During the same quarter in the previous year, the company posted $1.67 earnings per share. The business’s revenue was up 2.0% on a year-over-year basis. On average, equities analysts forecast that Humana will post $9.24 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Thursday, October 13th will be paid a dividend of $0.29 per share. The ex-dividend date is Tuesday, October 11th. This represents a $1.16 annualized dividend and a yield of 0.67%. Humana’s payout ratio is 18.18%.
A number of institutional investors have recently bought and sold shares of HUM. Renaissance Technologies LLC boosted its position in Humana by 246.3% in the first quarter. Renaissance Technologies LLC now owns 446,000 shares of the insurance provider’s stock valued at $81,596,000 after buying an additional 317,200 shares during the last quarter. Arrowgrass Capital Partners US LP boosted its position in Humana by 1.8% in the first quarter. Arrowgrass Capital Partners US LP now owns 2,878,848 shares of the insurance provider’s stock valued at $526,685,000 after buying an additional 51,267 shares during the last quarter. Retirement Systems of Alabama boosted its position in Humana by 0.7% in the second quarter. Retirement Systems of Alabama now owns 75,981 shares of the insurance provider’s stock valued at $13,667,000 after buying an additional 531 shares during the last quarter. Bank of Montreal Can bought a new position in Humana during the second quarter valued at $14,049,000. Finally, Orbis Allan Gray Ltd bought a new position in Humana during the first quarter valued at $38,209,000. 93.27% of the stock is owned by institutional investors.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.